563 related articles for article (PubMed ID: 30728058)
1. Strategies of adoptive T -cell transfer to treat refractory viral infections post allogeneic stem cell transplantation.
Kaeuferle T; Krauss R; Blaeschke F; Willier S; Feuchtinger T
J Hematol Oncol; 2019 Feb; 12(1):13. PubMed ID: 30728058
[TBL] [Abstract][Full Text] [Related]
2. Adoptive T-cell transfer for refractory viral infections with cytomegalovirus, Epstein-Barr virus or adenovirus after allogeneic stem cell transplantation.
Feucht J; Joachim L; Lang P; Feuchtinger T
Klin Padiatr; 2013 May; 225(3):164-9. PubMed ID: 23700092
[TBL] [Abstract][Full Text] [Related]
3. Antigenic competition in the generation of multi-virus-specific cell lines for immunotherapy of human cytomegalovirus, polyomavirus BK, Epstein-Barr virus and adenovirus infection in haematopoietic stem cell transplant recipients.
Roubalová K; Němečková Š; Kryštofová J; Hainz P; Pumannová M; Hamšíková E
Immunol Lett; 2020 Dec; 228():64-69. PubMed ID: 33031870
[TBL] [Abstract][Full Text] [Related]
4. Addition of varicella zoster virus-specific T cells to cytomegalovirus, Epstein-Barr virus and adenovirus tri-specific T cells as adoptive immunotherapy in patients undergoing allogeneic hematopoietic stem cell transplantation.
Ma CK; Blyth E; Clancy L; Simms R; Burgess J; Brown R; Deo S; Micklethwaite KP; Gottlieb DJ
Cytotherapy; 2015 Oct; 17(10):1406-20. PubMed ID: 26349000
[TBL] [Abstract][Full Text] [Related]
5. Safe adoptive transfer of virus-specific T-cell immunity for the treatment of systemic adenovirus infection after allogeneic stem cell transplantation.
Feuchtinger T; Matthes-Martin S; Richard C; Lion T; Fuhrer M; Hamprecht K; Handgretinger R; Peters C; Schuster FR; Beck R; Schumm M; Lotfi R; Jahn G; Lang P
Br J Haematol; 2006 Jul; 134(1):64-76. PubMed ID: 16803570
[TBL] [Abstract][Full Text] [Related]
6. Early cytomegalovirus reactivation leaves a specific and dynamic imprint on the reconstituting T cell compartment long-term after hematopoietic stem cell transplantation.
Lugthart G; van Ostaijen-Ten Dam MM; Jol-van der Zijde CM; van Holten TC; Kester MG; Heemskerk MH; Bredius RG; van Tol MJ; Lankester AC
Biol Blood Marrow Transplant; 2014 May; 20(5):655-61. PubMed ID: 24462981
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy for transplantation-associated viral infections.
Roddie C; Peggs KS
J Clin Invest; 2017 Jun; 127(7):2513-2522. PubMed ID: 28628043
[TBL] [Abstract][Full Text] [Related]
8. Clinical grade generation of hexon-specific T cells for adoptive T-cell transfer as a treatment of adenovirus infection after allogeneic stem cell transplantation.
Feuchtinger T; Richard C; Joachim S; Scheible MH; Schumm M; Hamprecht K; Martin D; Jahn G; Handgretinger R; Lang P
J Immunother; 2008; 31(2):199-206. PubMed ID: 18481389
[TBL] [Abstract][Full Text] [Related]
9. Safety and clinical efficacy of rapidly-generated trivirus-directed T cells as treatment for adenovirus, EBV, and CMV infections after allogeneic hematopoietic stem cell transplant.
Gerdemann U; Katari UL; Papadopoulou A; Keirnan JM; Craddock JA; Liu H; Martinez CA; Kennedy-Nasser A; Leung KS; Gottschalk SM; Krance RA; Brenner MK; Rooney CM; Heslop HE; Leen AM
Mol Ther; 2013 Nov; 21(11):2113-21. PubMed ID: 23783429
[TBL] [Abstract][Full Text] [Related]
10. Off-the-Shelf Virus-Specific T Cells to Treat BK Virus, Human Herpesvirus 6, Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections After Allogeneic Hematopoietic Stem-Cell Transplantation.
Tzannou I; Papadopoulou A; Naik S; Leung K; Martinez CA; Ramos CA; Carrum G; Sasa G; Lulla P; Watanabe A; Kuvalekar M; Gee AP; Wu MF; Liu H; Grilley BJ; Krance RA; Gottschalk S; Brenner MK; Rooney CM; Heslop HE; Leen AM; Omer B
J Clin Oncol; 2017 Nov; 35(31):3547-3557. PubMed ID: 28783452
[TBL] [Abstract][Full Text] [Related]
11. Curative or pre-emptive adenovirus-specific T cell transfer from matched unrelated or third party haploidentical donors after HSCT, including UCB transplantations: a successful phase I/II multicenter clinical trial.
Qian C; Campidelli A; Wang Y; Cai H; Venard V; Jeulin H; Dalle JH; Pochon C; D'aveni M; Bruno B; Paillard C; Vigouroux S; Jubert C; Ceballos P; Marie-Cardine A; Galambrun C; Cholle C; Clerc Urmes I; Petitpain N; De Carvalho Bittencourt M; Decot V; Reppel L; Salmon A; Clement L; Bensoussan D
J Hematol Oncol; 2017 May; 10(1):102. PubMed ID: 28482908
[TBL] [Abstract][Full Text] [Related]
12. T cells for viral infections after allogeneic hematopoietic stem cell transplant.
Bollard CM; Heslop HE
Blood; 2016 Jun; 127(26):3331-40. PubMed ID: 27207801
[TBL] [Abstract][Full Text] [Related]
13. Adoptive cellular therapy for cytomegalovirus infection following allogeneic stem cell transplantation using virus-specific T cells.
Mackinnon S; Thomson K; Verfuerth S; Peggs K; Lowdell M
Blood Cells Mol Dis; 2008; 40(1):63-7. PubMed ID: 17869548
[TBL] [Abstract][Full Text] [Related]
14. Adoptive transfer of antigen-specific T-cells of donor type for immunotherapy of viral infections following allogeneic hematopoietic cell transplants.
O'Reilly RJ; Doubrovina E; Trivedi D; Hasan A; Kollen W; Koehne G
Immunol Res; 2007; 38(1-3):237-50. PubMed ID: 17917029
[TBL] [Abstract][Full Text] [Related]
15. Transfer of Hexon- and Penton-selected adenovirus-specific T cells for refractory adenovirus infection after haploidentical stem cell transplantation.
Schultze-Florey RE; Tischer-Zimmermann S; Heuft HG; Priesner C; Lamottke B; Heim A; Sauer M; Sykora KW; Blasczyk R; Eiz-Vesper B; Maecker-Kolhoff B
Transpl Infect Dis; 2020 Feb; 22(1):e13201. PubMed ID: 31643129
[TBL] [Abstract][Full Text] [Related]
16. Clinical trials with CMV-specific T cells.
Peggs KS; Mackinnon S
Cytotherapy; 2002; 4(1):21-8. PubMed ID: 11953038
[TBL] [Abstract][Full Text] [Related]
17. Cellular therapy for multiple pathogen infections after hematopoietic stem cell transplant.
Sutrave G; Blyth E; Gottlieb DJ
Cytotherapy; 2017 Nov; 19(11):1284-1301. PubMed ID: 28927824
[TBL] [Abstract][Full Text] [Related]
18. Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines.
Peggs KS; Verfuerth S; Pizzey A; Khan N; Guiver M; Moss PA; Mackinnon S
Lancet; 2003 Oct; 362(9393):1375-7. PubMed ID: 14585640
[TBL] [Abstract][Full Text] [Related]
19. Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation.
Leen AM; Christin A; Myers GD; Liu H; Cruz CR; Hanley PJ; Kennedy-Nasser AA; Leung KS; Gee AP; Krance RA; Brenner MK; Heslop HE; Rooney CM; Bollard CM
Blood; 2009 Nov; 114(19):4283-92. PubMed ID: 19700662
[TBL] [Abstract][Full Text] [Related]
20. Third-party CMV- and EBV-specific T-cells for first viral reactivation after allogeneic stem cell transplant.
Jiang W; Clancy LE; Avdic S; Sutrave G; Street J; Simms R; McGuire HM; Patrick E; Chan AS; McCaughan G; Myers N; Micklethwaite KP; Antonenas V; Selim AG; Ritchie D; Bateman CM; Shaw PJ; Blyth E; Gottlieb DJ
Blood Adv; 2022 Sep; 6(17):4949-4966. PubMed ID: 35819448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
